To develop drugs that uniquely meet the needs and improve the lives of patients with cardiorenal disease, infectious disease and inflammatory disease.

KBP-5074 for CV disease/Hypertension in CKD patients – Finish Phase 2a / Ready for global Phase 2b

KBP-7072 for multiple drug resistant infections– Finish Phase 1 / Ready for global Phase 2

KBP-7026 novel CRTH2 receptor antagonist targeting asthma/COPD -- Ready for Phase 1

Read More

• Zhenhua Huang, PhD/MBA, Founder/Chairman
• Fred Yang, PhD,CDO
• Robert Segal, MD,Deputy CMO
• Vince Benn, PhD/MBA,VP
• Pual Chow, PhD,VP
• Wayne W. Lai, PhD,VP, President/KBP China

• Bertram Pitt, MD (US)
• George Bakris, MD (US)
• John McMurray, MD (UK)
• Faiez Zannad, MD (FR)
• Ricard Wunderink, MD (US)

Read More

KBP Biosciences Co., Ltd. attended the 2017 China BioMed Innovation and Investment Conference.

Careers Information updated on 27 July, 2017

Positive FDA Type B Meeting on KBP-5074

KBP-7072 obtained QIDP and Fast Track Designations

Presenting the annual meeting of the American Society of Nephrology (ASN)

Read More

Contact Us

Fred Yang, Ph.D, Chief Development Officer

116 Village Blvd., Suite 210 Princeton, NJ 08540      Phone: (609) 531-0889(Office) / (267)980-9451(Cell)